In Switzerland, cases of sexually transmitted infections (STIs) have surged over the past 15 years, notably with a marked increase in chlamydia, gonorrhea, and syphilis. However, the key to containment lies in early testing, which has proven to be expensive and often a financial burden on individuals.

Early tests play a crucial role in timely diagnosis and treatment, safeguarding the health of the population. Alarmingly, studies indicate that up to 80 percent of infected individuals show no symptoms, unknowingly contributing to the spread of infections.

Compounding the issue, STI tests in Switzerland are typically self-funded, with health insurance covering costs only under clear indications and high franchises. A survey reveals significant price variations, ranging from 90 francs in Biel to 300 francs in Graubünden.

The financial strain discourages many from undergoing tests, even when infection is suspected. Left untreated, STIs can lead to severe health consequences such as infertility and contribute to the further spread of infections.

Criticism of the high laboratory costs in Switzerland has come from both the price supervisor and health insurance association Santésuisse. Addressing and reducing these costs could potentially enhance accessibility to tests.

In response to these challenges, the association of medical laboratories contends that the price comparison with foreign countries is insufficient, citing higher personnel and infrastructure costs.They argue that different tariff structures and decentralized supply models must be taken into account.

Specialists and AIDS Aid Switzerland advocate for:

1. Free or Affordable Tests: Health authorities should intervene to make STI testing more accessible by offering tests for free or at reduced costs, encouraging regular testing.
2. Education Campaigns: Raising awareness about STIs and prevention is critical. Effective campaigns can dispel prejudices, reduce stigma, and motivate people to get tested.

Experts emphasize that Switzerland must seriously confront the growing challenge of STIs by implementing measures to reduce their spread. Affordable testing and lower laboratory costs are seen as crucial components for building a healthier society and mitigating the number of STI infections.

Linda Nartey, Deputy Director and President-in-Cover at the Federal Office of Public Health (FOPH), acknowledges the issue of high STI testing costs and emphasizes the need for “correct and not too expensive prices” in a recent “Kassensturz” interview. It highlights the importance of collaborative efforts to address this public health concern.